Methylphenidate is a stimulant medicine used to treat attention deficit hyperactivity disorder (ADHD). Ritalin is one brand name, but it is not a synonym for every methylphenidate product.
That distinction matters because methylphenidate preparations do not all release the drug in the same way. Some act relatively quickly and require more than one dose across the day; others are modified-release products designed to work for longer. Switching brands or formulations can change the timing of effect even when the active ingredient is the same.
Where methylphenidate fits in ADHD treatment
NICE recommends methylphenidate as a first-line pharmacological option for children aged five and over and young people with ADHD when medication is indicated. For adults, NICE recommends either methylphenidate or lisdexamfetamine as first-line pharmacological treatment.
Medication is not used simply because somebody recognises ADHD traits in themselves. Diagnosis and treatment decisions require an appropriate clinical assessment, including the degree of impairment and other possible explanations for symptoms.
How methylphenidate works
Methylphenidate increases activity in brain systems involving dopamine and noradrenaline. In people with ADHD, this can improve attention, reduce impulsivity and make it easier to regulate activity and behaviour.
The NHS notes that the medicine may begin working within 30 to 60 minutes once the right preparation and dose have been established, although finding that regimen can take time.
Immediate-release and modified-release are not interchangeable in practice
Standard tablets release methylphenidate relatively quickly. Modified-release tablets and capsules are designed to release it over a longer period.
Different modified-release brands use different release patterns. The NHS therefore advises people to stick to the same brand where possible because a change can alter how the medicine works across the day.
This is a good example of why “10 mg is 10 mg” is not always the whole story with medicines. Timing of delivery can be clinically important.
Common side effects
Headache, reduced appetite, difficulty sleeping and stomach symptoms can occur. Because methylphenidate is a stimulant, pulse and blood pressure also matter.
NICE recommends baseline assessment before ADHD medication, including relevant cardiovascular history and blood pressure and pulse measurements. Ongoing monitoring is part of treatment rather than an optional extra.
Changes in mood or behaviour also deserve attention, particularly when they appear after starting treatment or changing the dose.
Growth and appetite in younger patients
Reduced appetite can matter more in children and adolescents because persistent appetite suppression may affect weight gain. NICE guidance therefore includes height and weight monitoring during treatment.
This does not mean methylphenidate inevitably causes clinically important growth problems. It means treatment should be monitored rather than judged solely by whether concentration improves.
Why a stimulant can be appropriate for ADHD
The word “stimulant” sometimes creates understandable confusion. People may assume a stimulant should make hyperactivity worse.
ADHD treatment is not based on sedating someone. Properly prescribed stimulant treatment can improve regulation of attention and impulse control through its effects on relevant neurotransmitter systems.
The clinical question is whether symptoms and functioning improve at a tolerable level of side effects.
Misuse and diversion
Methylphenidate has misuse potential, which is one reason it is controlled. Tablets or capsules prescribed to one person should not be shared with another, even where the other person believes they have ADHD.
Non-medical use also changes the context completely. A prescribed regimen includes formulation choice, dose adjustment, screening and monitoring. Using someone else’s medication removes those safeguards.
Can methylphenidate cause dependence?
Methylphenidate is a controlled stimulant and can be misused. Therapeutic treatment and stimulant addiction should not be treated as the same thing, however.
Dependence risk needs to be considered alongside dose, route, pattern of use and whether the medicine is being taken as prescribed. Sudden changes to prescribed treatment should be discussed with the clinician rather than improvised.
The NHS advises patients not to stop methylphenidate suddenly without speaking to their doctor.
Cardiovascular assessment is part of prescribing
Before medication starts, NICE recommends checking for cardiovascular features that may require further assessment, including exertional fainting, certain patterns of palpitations, cardiac-type chest pain, heart murmurs and hypertension.
Routine ECG testing is not required for every patient without an indication. The point is targeted assessment, not indiscriminate testing.
Is Ritalin the same as methylphenidate?
Ritalin contains methylphenidate, but methylphenidate is also sold under several other brand names. NHS information lists brands including Concerta, Delmosart, Equasym and Medikinet.
Because release characteristics vary, a clinician or pharmacist may specify a particular preparation rather than treating all brands as automatically interchangeable.
UK controlled-drug status
Methylphenidate is a Class B controlled drug in the UK and is available only on prescription.
The NHS notes additional controlled-drug requirements around collection of prescriptions. GOV.UK lists methylphenidate, including Ritalin, under Class B.
Unauthorised possession of a Class B drug can carry a maximum penalty of five years in prison, an unlimited fine, or both. Supply and production can carry up to 14 years.
Buying methylphenidate online
A website offering Ritalin or other methylphenidate without an appropriate prescription should not be treated as equivalent to a regulated pharmacy. Controlled medicines require legitimate prescribing and supply arrangements.
Packaging and tablet markings cannot prove that an online product is authentic.
See our guide to buying Ritalin or methylphenidate online in the UK for the regulatory and counterfeit-medicine issues.
